Developer of gene therapies to treat genetic diseases. The company uses a proprietary Plato platform to develop lentiviral gene therapies for lysosomal disorders. The product pipeline includes AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 Hunter syndrome. The company was founded in 2016 and headquartered in Cambridge, United States. It has raised $85.5M in series b funding, with backing from Citadel, Brace Pharma Capital, Eventide Funds, Atlas Venture, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Gene Therapy, Life Sciences - Rare Diseases space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.
← All startups
Avrobio
Series BDeveloper of gene therapies to treat genetic diseases. The company uses a proprietary Plato platform to develop lentiviral gene therapies for lysosomal disorders. The product pipeline includes AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 Hunter syndrome. The company was founded in 2016 and headquartered in Cambridge, United States. It has raised $85.5M in series b funding, with backing from…
About
Business model
Rare Diseases > Drugs > Metabolic Disorders > Lysosomal Diseases,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
CitadelBrace Pharma CapitalEventide FundsAtlas VentureSV Health InvestorsBlackstoneMorningsideAisling CapitalCormorant Asset ManagementJLABS
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.